In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
GoodRx said in a statement that it is working with Sanofi to offer U.S. insulin patients a coupon for to a 30-day supply of Lantus, an insulin glargine injection and Sanofi's most widely ...
Lilly and Boehringer Ingelheim have gained EU approval for their biosimilar version of Sanofi's blockbuster insulin product Lantus (insulin glargine). The Europe-wide approval is the first ever ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.